Novelty. Technology. Care.

Leading Italian pharmaceutical company driving global innovation in ophthalmology and specialized therapeutic areas



Agenda

01_ **Company Overview & Global Reach**

Our position in international pharmaceutical markets

02_**R&D Excellence**

Innovation pipeline and clinical programs

03_**Product Portfolio**

Leading solutions in ophthalmology and specialties

04_**Growth strategy**

Mutual development and shared success in global markets

ntc
Novelty. Technology. Care.

Global Reach

Network

300+ partners across **100+ countries** ensuring worldwide access to innovative therapeutic solutions



Innovation

R&D-driven approach with **€50M investment** by 2027 for next-generation medicines

Excellence

First Italian ophthalmology company to launch globally with proven clinical success

23 products marketed in over 15 countries worldwide

ntc
Novelty. Technology. Care.

R&D Excellence

Research Pipeline

11 interventional **clinical studies** currently sponsored

17 scientific advice approvals from regulatory authorities

Intellectual Property

278 European patents securing market exclusivity

56 national patents protecting key innovations

10 PCT applications for worldwide protection

8 Eurasian patents

Clinical Excellence

90 peer-reviewed publications validating therapeutic approaches

Nearly **3.000 patients** enrolled in comprehensive clinical programs

Largest European clinical program in cataract surgery


Focus on antimicrobial resistance and rational antibiotic use

ntc
Novelty. Technology. Care.

Pipeline

*Our comprehensive clinical pipeline addresses critical **unmet medical needs** across ophthalmology, otology, and gastroenterology.*

*Each program is designed to fight **antimicrobial resistance** while delivering superior patient outcomes through **innovative therapeutic combinations** and advanced formulation technologies.*



ntc
Novelty. Technology. Care.

Product portfolio

GLAUCOMA
IOP-lowering drops
Nutraceuticals

POST-CATARACT TREATMENT
Fixed-dose combination

OCULAR INFECTION
Antibiotics

OCULAR INFLAMMATION
Steroids

MILD-TO-MODERATE DRY EYE
Artificial tears

MODERATE-TO-SEVERE DRY EYE
Artificial tears

CORNEAL REPAIR
Re-epithelializing gel

CORNEAL EDEMA
Hypertonic agents



BLEPHARITIS
Wipes and warming compresses

EYELID CLEANSING/ANTISEPTIC
Wipes

MYODESOPSIA
Nutraceuticals

RETINAL DISEASES
Nutraceuticals

ALLERGY
Sprays and antihistamines

GLAUCOMA:
IN TREATING IOP, YOU HAVE TWO OPTIONS

REDUCE HA PRODUCTION

- Beta-blockers
- Carbonic Anhydrase Inhibitors
- Alpha agonists



INCREASE HA OUTFLOW

- Prostaglandin analogues
- Miotics
- Alpha agonists


ntc
Novelty. Technology. Care.

Product portfolio



GASTRO-METABOLISM

- Bowel preparation: powder for oral solution
- Meteorism: different pharmaceutical forms
- Hemorrhoids: gel
- IBS: probiotics
- Mouth ulcers: gel, mouthwash and spray
- Liver protection: nutraceuticals



GYNECOLOGY

- Vaginal infection: gel, softgel caps and probiotic
- Vaginal atrophy: gel
- Vaginal discomfort: gel, foam, wipes
- Mucosal repair: gel
- Iron deficiency: nutraceuticals




SUPPORTIVE CARE

- Wound healing: cream and spray
- Atopic dermatitis: gel
- Diabetic foot: cream

ntc
Novelty. Technology.

The future of MD portofolio



EU-MDR certified

26 Medical devices have been already MDR approved

13 Medical devices already submitted to the NB: under assessment

5 Medical devices to be submitted to the NB

ntc Novelty. Technology. Care.

90% *Combination of MDR Approved and Submitted*

Update July 2026

Growth strategy


MARKET EXECUTION 2025

New deals:
70+

Units sold:
32 million units worldwide

Partners:
300+ partners in 100+ markets

Global Medical Marketing Meetings:
"Growing Together" event in Venice, engaging KOLs and Distributors:
12 KOLs
120 attendees
36 companies
40 roundtables





700+ deals across 100+ countries

40 launches of NTC products in 2025

ntc
Novelty. Technology. Care.

Sustainable Growth



EcoVadis is a globally recognized sustainability assessment platform that evaluates companies across environmental, social, ethical and sustainable procurement criteria.

NTC successfully completed the EcoVadis 2026 assessment, achieving an overall score of **63/100** and earning the Committed Badge. This result places NTC in the **61st percentile** among companies assessed by EcoVadis.

The assessment highlighted positive results across all evaluated areas:

- **Labour & Human Rights**
- **Ethics**
- **Environment**
- **Sustainable Procurement**

*"These results reflect NTC's commitment to fostering a **responsible workplace**, conducting business with **integrity**, managing **environmental impacts** and promoting **sustainable** practices throughout our value chain."* Riccardo Carbucicchio, CEO

ntc
Novelty. Technology. Care.


NTC overview

Manufacturing

45 CDMOs/CMOs

68% of the procurement budget for products is allocated to Italian suppliers

Turnover by therapeutic areas



R&D

€ 50 million invested*

11 controlled clinical studies

17 Scientific Advice procedures

3,000 patients enrolled in clinical studies

90 publications covering our entire portfolio

*By 2027

Environment

42% of turnover comes from green products

***85 tons** of marine litter collected through NTC initiatives (*jan-Dec 2025)

Social

119 employees*

4 generation in NTC:

Baby Boomers **6%**

Millennials **40%**

Gen X **49%**

Gen Z **5%**

* 132 employees - update July 2026

Patents

278 European patents

56 National Patents

13 Priority Documents

10 Patent Cooperation Treaty

8 Eurasian Patents

365 Total Patents

Governance

73% of NTC suppliers have signed our Code of Conduct

B2B

300+ partners in

100+ markets

B2C

2 ophthalmology franchises in **Italy** and **Spain**

Products

120+ products available

700+ SKUs marketed

4 in-licensing agreements

OUR CORPORATE POSITIONING

"NTC aims to innovate patients' experiences and the practice of care, based of four fundamental pillars"


Sustainability

Favoring a more ethical consumption and adoption of a healthcare praxis that prevents the overuse of drugs, researching and developing drugs designed to fight antibiotic resistance and the indiscriminate use of antihistamines




Technology

Shifting from a disease-centered to an individual-centered approach, researching solutions that innovate the administration of the product to promote a better sensory experience for the user



Simplification

Improving patients' compliance with treatment processes and therapies, researching new solutions that reduce the frequency and duration of therapy, and facilitate better ways of taking medications



Balance


Increasing patients' active participation and control of therapies, developing solutions that adapt to the rhythm of the body and leverage patients' ability to perceive changes and pursue a consciously balanced relationship with their body



ntc
Novelty. Technology. Care.

Thank you for your attention



ntc
Novelty. Technology. Care.